Market Research Report
Hyperalgesia - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||293882|
|Published||Content info||37 Pages
Delivery time: 1-2 business days
|Hyperalgesia - Pipeline Review, H2 2019|
|Published: August 30, 2019||Content info: 37 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia - Pipeline Review, H2 2019, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape.
Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and Non-steroidal anti-inflammatory drugs.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperalgesia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.